Drug Trial Radar · NCT04752722
LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
Last checked: Nov 19, 2026Latest source record: Aug 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
350
Planned (sponsor's estimate)
Start
Apr 22, 2021
Primary completion
Apr 30, 2028
Study completion Oct 30, 2030
Sponsor
- Lead sponsor
- enGene, Inc.Industry
- Sponsor type
- Industry
- First posted
- Feb 12, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the safety and efficacy of intravesical administration of detalimogene (EG-70) in the bladder and its effect on bladder tumors in patients with NMIBC. This study study consists of two phases; a Phase 1 dose-escalation to establish safety and recommended the phase 2 dose, followed by a Phase 2 study to establish how effective the treatment is. The Study will include patients with: NMIBC with CIS for whom BCG therapy is unresponsive, and other high risk patients with NMIBC. A Substudy will include a surfactant bladder rinse prior to the instillation of detalimogene in patients with NMIBC with CIS for whom BCG therapy is unresponsive.
Conditions
- Superficial Bladder Cancer
- Non-muscle Invasive Bladder Cancer With Carcinoma in Situ
- Non-muscle Invasive Bladder Cancer
Interventions
EG-70 (phase 1)Drug
Patients will receive up to four cycles of EG-70 administered as a bladder instillation of a 50 mL volume of study drug via catheter with a targeted retention time of 60 minutes.One cycle lasts approximately 12 weeks and consists of either a 2-dose (Day 1 and Day 8) or 4-dose (Day 1, Day 8, Day 29 and Day 36) regimen.
EG-70 (phase 2) Master ProtocolDrug
Under the Treatment Period, patients will receive 4 instillations per cycle for up to 4 cycles, of EG-70 at the RP2D defined in Phase 1, administered as a bladder instillation of a 50 mL volume of study drug via catheter with a targeted retention time of 60 minutes. One cycle lasts approximately 12 weeks. For Maintenance treatment 2 doses of EG-70 will be administered as a bladder instillation per 12-week cycle.
Surfactant Bladder Pre-Rinse and EG-70 (Substudy)Drug
Patients will receive via catheter a 50 mL volume of a 5-minute bladder rinse immediately prior to administration of 50 mL of detalimogene voraplasmid (EG-70) at the RP2D for 30 minutes. During the Treatment Period, patients will receive 4 instillations per cycle for up to 4 cycles of the sudy intervention. One cycle lasts approximately 12 weeks. For Maintenance treatment, 2 doses of the study intervention will be administered as a bladder instillation per 12-week cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1: Nature, incidence, relatedness, and severity of all AEs and SAEs according to the CTCAE v5.0.Time frame: Approximately 2 years
- Phase 2: Percentage of patients with cystoscopic CR at any time, based on exam, urine cytology and appropriate biopsies.Time frame: Approximately 24 weeks
- Phase 2: Nature, incidence, relatedness, and severity of treatment emergent adverse events (as assessed by CTCAE v5.0)Time frame: Approximately 3 years
Locations
102 sites in 10 countries. Site status is shown where the registry gives one.
The University of Alabama at Birmingham Clinical Research Unit (CRU)
Birmingham, Alabama · Recruiting
Mayo Clinic
Scottsdale, Arizona · Recruiting
Urological Associates of South Arizona
Tucson, Arizona · Completed
Arkansas Urology
Little Rock, Arkansas · Recruiting
University of California - Irvine Medical Center
Irvine, California · Recruiting
UC San Diego Moores Cancer Center
La Jolla, California · Recruiting
USC/Norris Comprehensive Cancer Center
Los Angeles, California · Recruiting
Tower Urology
Los Angeles, California · Recruiting
Om Research
San Diego, California · Recruiting
Colorado Clinical Research
Lakewood, Colorado · Recruiting
The George Washington Medical Faculty Associates
Washington D.C., District of Columbia · Recruiting
University of Florida
Jacksonville, Florida · Recruiting
Sylvester Comprehensive Cancer Center / University of Miami Hospital and Clinics
Miami, Florida · Recruiting
Emory University
Atlanta, Georgia · Recruiting
Georgia Cancer Center at Augusta University
Augusta, Georgia · Recruiting
Urology of Indiana
Greenwood, Indiana · Recruiting
University of Kansas Medical Center
Kansas City, Kansas · Recruiting
John Hopkins Hospital
Baltimore, Maryland · Recruiting
Chesapeake Urology Research Associates
Hanover, Maryland · Recruiting
Brigham and Women's Hospital
Boston, Massachusetts · Recruiting
Henry Ford Health System
Detroit, Michigan · Recruiting
Corewell Health Medical Group and Spectrum Health Hospitals
Grand Rapids, Michigan · Recruiting
University of Minnesota
Minneapolis, Minnesota · Recruiting
Mayo Clinic
Rochester, Minnesota · Recruiting
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey · Recruiting
New Jersey Urology, LLC
Voorhees Township, New Jersey · Recruiting
Albany Medical College
Albany, New York · Recruiting
Roswell Park Cancer Institute
Buffalo, New York · Recruiting
Mount Sinai Medical Center
New Haven, New York · Recruiting
Laura & Isaac Perlmutter Cancer Center at NYU Langone Health
New York, New York · Completed
Associated Medical Professionals of NY,
Syracuse, New York · Recruiting
UNC Chapel Hill Hospital
Chapel Hill, North Carolina · Recruiting
Duke Health - Duke Cancer Center
Durham, North Carolina · Recruiting
Associated Urologists of North Carolina
Raleigh, North Carolina · Recruiting
University of Cincinnati Medical Center
Cincinnati, Ohio · Recruiting
Central Ohio Urology Group
Gahanna, Ohio · Recruiting
Clinical Research Solutions - Helios Clinical Research
Middleburg Heights, Ohio · Recruiting
Oregon Health & Science University (OHSU)
Portland, Oregon · Recruiting
Thomas Jefferson University, Sidney Kimmel Cancer Center
Philadelphia, Pennsylvania · Recruiting
Carolina Urologic Research Center, LLC
Myrtle Beach, South Carolina · Recruiting
Showing 40 of 102 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.